MissionIR News - PROLOR Biotech to Present Positive Phase 2 Data at ESPE2012

Trial results of company’s human growth hormone therapy, hGH-CTP, slated for poster presentation

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
We welcome the opportunity to raise awareness of our progress with hGH-CTP...

Atlanta, Georgia (PRWEB) September 22, 2012

MissionIR would like to highlight PROLOR Biotech, Inc., a publicly traded development stage biopharmaceutical company, engaged in the development of proprietary versions of already-approved therapeutic proteins. Its technology, Carboxyl Terminal Peptide technology could be attached to an array of existing therapeutic proteins, stabilizing the therapeutic protein in the bloodstream and extending its life span without additional toxicity or loss of desired biological activity.

In the company’s news yesterday,

PROLOR Biotech announced that data from the company’s phase 2 trial of hGH-CTP for application to growth hormone deficient adults will be presented at ESPE 2012, the 51st Annual Meeting of the European Society for Pediatric Endocrinology.

The previously reported phase 2 study confirms hGH-CTP as a single weekly injection vs. the current standard-CTP of one injection per day. For a child receiving growth hormone replacement therapy, the total dosing by current daily standards would mean more than 3,000 injections before the age of 18.

“hGH-CTP has the potential to dramatically reduce this number, thereby making growth hormone therapy less burdensome and more feasible,” Dr. Abraham Havron, CEO of PROLOR stated in the press release. “We welcome the opportunity to raise awareness of our progress with hGH-CTP at this meeting of pediatric endocrinology opinion leaders.”

In addition, the study showed that 50%-65% of the cumulative weekly dose of conventional human growth hormone was required for the majority of the patients to remain within the normal range of IGF-1, a key biomarker of growth hormone activity.

In this trial, hGH-CTP demonstrated a good safety and tolerability profile. The treatment did not cause excessive IGF-1 levels in patients; nor was any IGF-I accumulation observed.

Positive phase 2 data in adults tipped the scale toward the company’s decision to continue with a phase 2 hGH-CTP trial in growth hormone deficient children that is currently enrolling patients.

The pediatric phase 2 trial is designed to compare the 12-month growth velocity of children receiving hGH-CTP injected once weekly with those receiving commercially available hGH injected daily.

The company’s poster, titled Once-Weekly, CTP-Modified hGH (MOD-4023) Effectively Maintains IGF-1 Levels Within the Normal Range in Growth Hormone Deficient Adults, Supporting Initiation of Clinical Development in Children, will be presented during the September 22, 2012 poster session of ESPE 2012 in Leipzig, Germany.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.


Contact